Keqiang Li

Dr. Keqiang Li

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2024 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
KLKeqiang Li
Keqiang Li
ZHZhenlin Huang
Zhenlin Huang
GXGuoqing Xie
Guoqing Xie
BHBudeng Huang
Budeng Huang
LSLiang Song
Liang Song
JYJinjian Yang
Jinjian Yang
Background: Upper tract urothelial carcinoma (UTUC) is a rare disease, belonging to the same category of urothelial cancers as bladder cancer (BC). Despite sharing similar non-surgical treatment modalities, UTUC demonstrates a higher metastasis propensity than BC. Furthermore, although both cancers exhibit similar molecular disease emergence mechanisms, sequencing data reveals some differences. Our study investigates the transcriptomic distinctions between UTUC and BC, explores the causes behind UTUC's heightened metastatic tendency, constructs a model for UTUC metastasis and prognosis, and propose personalized treatment strategies for UTUC. Methods: In our research, we utilized differential gene expression analysis, interaction networks, and Cox regression to explore the enhanced metastatic propensity of UTUC. We formulated and validated a prognostic risk model using diverse techniques, including cell co-culture, reverse transcription quantitative polymerase chain reaction (rt-qPCR), western blotting, and transwell experiments. Our methodological approach also involved survival analysis, risk model construction, and drug screening leveraging the databases of CTRPv2, PRISM and CMap. We used the Masson staining technique for histological assessments. All statistical evaluations were conducted using R software and GraphPad Prism 9, reinforcing the rigorous and comprehensive nature of our research approach. Results: Screening through inflammatory fibrosis revealed a reduction of extracellular matrix and cell adhesion molecules regulated by proteoglycans in UTUC compared with BC, making UTUC more metastasis-prone. We demonstrated that SDC1, LUM, VEGFA, WNT7B, and TIMP3, are critical in promoting UTUC metastasis. A risk model based on these five molecules can effectively predict the risk of UTUC metastasis and disease-free survival time. Given UTUC's unique molecular mechanisms distinct from BC, we discovered that UTUC patients could better mitigate the issue of poor prognosis associated with UTUC's easy metastasis through tyrosine kinase inhibitors (TKIs) alongside the conventional gemcitabine and cisplatin chemotherapy regimen. Conclusions: The poor prognosis of UTUC because of its high metastatic propensity is intimately tied to inflammatory fibrosis induced by the accumulation of reactive oxygen species. The biological model constructed using the five molecules SDC1, LUM, VEGFA, WNT7B, and TIMP3 can effectively predict patient prognosis. UTUC patients require specialized treatments in addition to conventional regimens, with TKIs exhibiting significant potential.

8 December 2025 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
GLGuanru Li
Guanru Li
EZErwei Zhang
Erwei Zhang
ZWZhiyu Wang
Zhiyu Wang
ZZZhijin Zhang
Zhijin Zhang
YZYuke Zhang
Yuke Zhang
KLKeqiang Li
Keqiang Li
Upper tract urothelial carcinoma (UTUC) is a rare malignancy with a significantly poorer prognosis than bladder cancer (BC). One distinguishing feature of UTUC is its enhanced resistance to reactive oxygen species (ROS)-induced lipid peroxidation, a phenomenon closely associated with adverse clinical outcomes. However, the molecular mechanisms underlying this resistance remain largely unexplored. In this study, we identify LncPEDS1-AS, an ultra-long (>6900 nt) antisense lncRNA, as a key regulator of ROS resistance in UTUC. Mechanistically, LncPEDS1-AS interacts with the splicing factor DDX23, forming a nuclear RNA-protein complex that facilitates the splicing and maturation of PEDS1 pre-mRNA. PEDS1 encodes plasmanylethanolamine desaturase, which plays a protective role against lipid peroxidation. Based on these findings, we developed an antisense oligonucleotide (ASO) therapy strategy targeting LncPEDS1-AS, which effectively suppressed tumour growth and enhanced tumour cells’ ROS sensitivity both in vitro and in vivo. Moreover, our findings also highlight the distinctive molecular features and regulatory capacity of ultra-long antisense lncRNAs such as LncPEDS1-AS, which merit further comprehensive exploration in cancer biology.

25 August 2025 in Journal of Pediatric Urology
Verified
Journal Article
Closed access
MSMingjia Shi
Mingjia Shi
GWGuangchun Wang
Guangchun Wang
KLKeqiang Li
Keqiang Li
XYXuefen Yu
Xuefen Yu

11 October 2023 in Research Square
Verified
Preprint
Open access
PDF file
KLKeqiang Li
Keqiang Li
ZHZhenlin Huang
Zhenlin Huang
GXGuoqing Xie
Guoqing Xie
BHBudeng Huang
Budeng Huang
LSLiang Song
Liang Song
JYJinjian Yang
Jinjian Yang
Background: Upper tract urothelial carcinoma (UTUC) is a rare disease, belonging to the same category of urothelial cancers as bladder cancer (BC). Despite sharing similar non-surgical treatment modalities, UTUC demonstrates a higher propensity for metastasis compared to BC. Additionally, while both cancers exhibit many similar molecular disease emergence mechanisms, sequencing data reveals some differences. Our study aims to understand the transcriptomic distinctions between UTUC and BC, explore the causes behind UTUC's heightened metastatic tendency, construct a model for UTUC metastasis and prognosis, and propose personalized treatment strategies for UTUC. Methods: In our research, we utilized differential gene expression analysis, interaction networks, and Cox regression to explore the enhanced metastatic propensity of UTUC. We formulated and validated a prognostic risk model using a diverse set of techniques, which include cell co-culture, reverse transcription quantitative polymerase chain reaction (rt-qPCR), Western blot, and Transwell experiments. Our methodological approach also involved survival analysis, risk model construction, and drug screening leveraging the databases of CTRPv2, PRISM and CMap. For histological assessments, we employed the Masson staining technique. All statistical evaluations were conducted using R software and GraphPad Prism 9, reinforcing the rigorous and comprehensive nature of our research approach. Results: Screening through inflammatory fibrosis revealed a reduction of extracellular matrix and cell adhesion molecules regulated by proteoglycans in UTUC compared to BC, making UTUC more metastasis-prone. We demonstrated that five molecules, SDC1, LUM, VEGFA, WNT7B, and TIMP3, play critical roles in promoting UTUC metastasis. A risk model based on these five molecules can effectively predict the risk of UTUC metastasis and disease-free survival time. Given UTUC's unique molecular mechanisms distinct from BC, we discovered that UTUC patients could better mitigate the issue of poor prognosis associated with UTUC's easy metastasis by using Tyrosine Kinase Inhibitors (TKIs) alongside the conventional gemcitabine and cisplatin chemotherapy regimen. Conclusions: 1. The poor prognosis of UTUC due to its high metastatic propensity is intimately tied to inflammatory fibrosis induced by ROS accumulation. 2. The biological model constructed using the five molecules SDC1, LUM, VEGFA, WNT7B, and TIMP3 can effectively predict patient prognosis. 3. UTUC patients require specialized treatments in addition to traditional regimens, with TKIs showing significant potential.

1 July 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
YZYuke Zhang
Yuke Zhang
SSShuxian Shen
Shuxian Shen
WLWeiyuan Li
Weiyuan Li
YHYangyang Hu
Yangyang Hu
YZYu Zhang
Yu Zhang
GWGuangchun Wang
Guangchun Wang
Introduction: Urothelial carcinoma of the bladder (UBC) and upper tract urothelial carcinoma (UTUC) are distinct malignancies with differing prognoses and molecular characteristics despite their shared histological origin. Emerging evidence suggests that chronic inflammation, often driven by specific carcinogenic exposures, plays a critical role in tumour development. While the oncogenic role of various chemical agents in UTUC is well established, the potential contribution of recurrent urolithiasis remains underappreciated and insufficiently studied. Given the frequent observation of inflammatory polyps surrounding upper tract calculi, further investigation into this association is warranted. Case presentation: This case series reports on three patients with UTUC in the context of recurrent urolithiasis. Case 1 involves a 53-year-old male patient with a history of repeated ureteric stones and inflammatory polyps who was later diagnosed with low-grade invasive urothelial carcinoma. Case 2 describes a 46-year-old female patient with bilateral renal calculi who developed high-grade invasive UTUC following long-standing calculus disease. Case 3 is a 57-year-old male patient who had recently ingested herbal medicine containing aristolochic acid and was found to have high-grade UTUC, with concurrent urolithiasis potentially contributing to carcinogenesis. In each instance, urothelial carcinoma was initially concealed by polypoid lesions surrounding impacted stones, highlighting the associated diagnostic challenges. Conclusion: This case series underscores the potential oncogenic role of chronic inflammation induced by recurrent upper urinary tract calculi. Persistent stone-related mucosal injury may contribute to UTUC pathogenesis. Clinicians should maintain a high index of suspicion and perform targeted biopsies of polypoid lesions encountered during the endoscopic management of urolithiasis. Enhanced awareness may facilitate earlier detection and intervention, particularly in patients with recurrent calculus disease.